Quinolones Market Report 2025

The quinolones market size has grown steadily in recent years. It will grow from $50.05 billion in 2024 to $52.39 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to antibiotic demand and usage, regulatory approvals, research and development, competitive landscape, patent expirations.

The quinolones market size is expected to see strong growth in the next few years. It will grow to $64.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to emerging diseases, regulatory changes, global health policies, rising antibiotic resistance, and market expansion strategies. Major trends in the forecast period include new product development, and changes in the regulatory landscape.

The rising incidence of infectious diseases is significantly driving the growth of the quinolones market. Infectious diseases refer to illnesses caused by microbes such as parasites, fungi, bacteria, and viruses. Quinolones are commonly used to treat a range of infectious diseases caused by bacteria, including tuberculosis and urinary tract infections. For instance, in November 2023, the Global Tuberculosis Report published by the World Health Organization, a health agency based in Switzerland, noted that the global number of newly diagnosed TB cases reached 7.5 million in 2022, an increase from 6.4 million in 2021. Therefore, the rise in infectious disease incidence is expected to propel the quinolones market.

The growing threat of antimicrobial resistance is anticipated to further boost the quinolones market in the future. Antimicrobial resistance (AMR) refers to the ability of microorganisms, including bacteria, viruses, parasites, and fungi, to withstand the effects of antimicrobial drugs. Quinolones have a broad spectrum of activity, making them effective against various bacteria. They are often prescribed for specific types of infections due to their ability to penetrate different tissues, becoming a preferred option when other treatments are limited. For instance, in July 2024, a report from the Centers for Disease Control and Prevention, a U.S.-based non-profit organization, indicated that antimicrobial-resistant infections surged by 20% between 2021 and 2022, and clinical cases of C. auris increased in 2022 compared to 2021. Therefore, the escalating threat of antimicrobial resistance is driving the growth of the quinolones market.

A prominent trend in the quinolones market is the emphasis on product innovation by major companies to sustain their market positions. For instance, in January 2023, Viatris, a US-based pharmaceutical company's South Korean branch introduced Dovprela, a novel treatment for drug-resistant tuberculosis. Dovprela, a three-drug regimen comprising bedaquiline, pretomanid, and linezolid (BPaL), offers a more rapid anti-tuberculosis effect, reducing the treatment period from 18-20 months to 5-6 months. This innovation addresses the pressing need for effective and efficient tuberculosis treatments.

Innovative products, such as fluoroquinolone antibiotic eye drops, are being introduced to drive revenues in the quinolones market. Fluoroquinolone antibiotic eye drops, a class of antibiotics targeting bacterial eye infections, contribute to ophthalmic health. For instance, Harrow Health Inc., a US-based pharmaceutical company, launched Vigamox in July 2023. This sterile ophthalmic solution, delivered in a 3-milliliter bottle, is indicated for the prevention of eye infections before and after surgery. Such innovative products cater to diverse medical needs and contribute to the market's growth.

In June 2023, Bausch + Lomb Incorporated, a US-based eye health company, acquired Novartis International AG for an undisclosed amount. Through this acquisition, Bausch + Lomb aims to restructure its pharmaceutical division, enhancing its scale and positioning it at the forefront of addressing ocular surface disorders. The acquisition diversifies Bausch + Lomb's product portfolio, introducing new opportunities such as libvatrep and AcuStream technology. Libvatrep is an experimental compound studied for treating chronic ocular surface pain, while AcuStream technology is an experimental device designed for accurate dosing and delivery of certain topical ophthalmic medications. Novartis International AG, based in Switzerland, is a pharmaceutical company with a global presence.

Major companies operating in the quinolones market include Bayer AG, Novartis AG, Sanofi SA, Merck & Co. Inc., LG Life Sciences, Pfizer Inc., Viatris Inc., Lupin Limited, Hikma Pharmaceuticals plc, Zydus Group, KYORIN Holdings Inc., Teva Pharmaceutical Industries Ltd., GSK plc, Zee Laboratories, Cipla Ltd., Geo Pharma Pvt. Ltd., Finecure Pharmaceuticals, Novus, AstraZeneca plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Ltd., Wockhardt Ltd.

North America was the largest region in the quinolones market in 2024. The regions covered in the quinolones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quinolones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Quinolones are a class of bactericidal antibiotics that exhibit the capability to directly kill bacterial cells, targeting both gram-positive and gram-negative bacteria. They are employed in the treatment of various infectious diseases caused by bacteria.

The primary types of quinolones include norfloxacin, ofloxacin, ciprofloxacin, gemifloxacin, and others. Norfloxacin, specifically a fluoroquinolone, is utilized for the treatment of diverse bacterial infections. Its applications extend to addressing conditions such as conjunctivitis and urinary tract infections, targeting both gram-positive and gram-negative pathogens. Quinolones are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The quinolones market research report is one of a series of new reports that provides, quinolones market statistics, including, quinolones industry global market size, regional shares, competitors with a quinolones market share, detailed, quinolones market segments, market trends and opportunities, and any further data you may need to thrive in the quinolones industry. This, quinolones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The quinolones market consists of sales of bedaquiline. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.